Patricia D Jones1, Michael D Kappelman, Christopher F Martin, Wenli Chen, Robert S Sandler, Millie D Long. 1. *Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; †Department of Medicine, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and ‡Division of Gastroenterology and Hepatology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Although exercise impacts quality of life in patients with inflammatory bowel disease, little is known about its role in disease activity. Among patients with inflammatory bowel disease in remission, we aimed to evaluate the association between exercise and subsequent active disease. METHODS: We performed a prospective study using the Crohn's and Colitis Foundation of America Partners' internet-based cohort of individuals with self-reported inflammatory bowel disease. We identified participants in remission, defined as short Crohn's disease activity index <150 or simple clinical colitis activity index ≤2. The primary exposure was exercise status, measured using the validated Godin leisure-time activity index. The primary study outcome, assessed after 6 months, was active disease defined using the above disease activity index thresholds. We used bivariate and multivariate analyses to describe the independent association between exercise and risk of active disease. RESULTS: We identified 1308 patients with Crohn's disease (CD) and 549 with ulcerative or indeterminate colitis (UC/IC) in remission, of whom 227 (17.4%) with CD and 135 (24.6%) with UC/IC developed active disease after 6 months. Higher exercise level was associated with decreased risk of active disease for CD (adjusted risk ratio: 0.72, 95% confidence interval: 0.55-0.94) and UC/IC (adjusted risk ratio: 0.78, 95% confidence interval: 0.54-1.13). CONCLUSIONS: In patients with CD in remission, those with higher exercise levels were significantly less likely to develop active disease at 6 months. In patients with UC/IC in remission, patients with higher exercise levels were less likely to develop active disease at 6 months; however this was not statistically significant.
BACKGROUND: Although exercise impacts quality of life in patients with inflammatory bowel disease, little is known about its role in disease activity. Among patients with inflammatory bowel disease in remission, we aimed to evaluate the association between exercise and subsequent active disease. METHODS: We performed a prospective study using the Crohn's and Colitis Foundation of America Partners' internet-based cohort of individuals with self-reported inflammatory bowel disease. We identified participants in remission, defined as short Crohn's disease activity index <150 or simple clinical colitis activity index ≤2. The primary exposure was exercise status, measured using the validated Godin leisure-time activity index. The primary study outcome, assessed after 6 months, was active disease defined using the above disease activity index thresholds. We used bivariate and multivariate analyses to describe the independent association between exercise and risk of active disease. RESULTS: We identified 1308 patients with Crohn's disease (CD) and 549 with ulcerative or indeterminate colitis (UC/IC) in remission, of whom 227 (17.4%) with CD and 135 (24.6%) with UC/IC developed active disease after 6 months. Higher exercise level was associated with decreased risk of active disease for CD (adjusted risk ratio: 0.72, 95% confidence interval: 0.55-0.94) and UC/IC (adjusted risk ratio: 0.78, 95% confidence interval: 0.54-1.13). CONCLUSIONS: In patients with CD in remission, those with higher exercise levels were significantly less likely to develop active disease at 6 months. In patients with UC/IC in remission, patients with higher exercise levels were less likely to develop active disease at 6 months; however this was not statistically significant.
Authors: Millie D Long; Wallace V Crandall; Ian H Leibowitz; Lynn Duffy; Fernando del Rosario; Sandra C Kim; Mark J Integlia; James Berman; John Grunow; Richard B Colletti; Bess T Schoen; Ashish S Patel; Howard Baron; Esther Israel; George Russell; Sabina Ali; Hans H Herfarth; Christopher Martin; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2010-12-17 Impact factor: 5.325
Authors: Siobhan F Clarke; Eileen F Murphy; Orla O'Sullivan; Alice J Lucey; Margaret Humphreys; Aileen Hogan; Paula Hayes; Maeve O'Reilly; Ian B Jeffery; Ruth Wood-Martin; David M Kerins; Eamonn Quigley; R Paul Ross; Paul W O'Toole; Michael G Molloy; Eanna Falvey; Fergus Shanahan; Paul D Cotter Journal: Gut Date: 2014-06-09 Impact factor: 23.059
Authors: Hilde E Ploeger; Tim Takken; Boguslaw Wilk; Robert M Issenman; Ryan Sears; Soni Suri; Brian W Timmons Journal: J Pediatr Date: 2010-12-10 Impact factor: 4.406
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Xiaomei Liao; Leslie M Higuchi; Charles S Fuchs; Donna Spiegelman; James M Richter; Joshua R Korzenik; Andrew T Chan Journal: BMJ Date: 2013-11-14
Authors: Wolfgang Alexander Seeger; Juliane Thieringer; Philip Esters; Benjamin Allmendinger; Jürgen Stein; Hermann Schulze; Axel Dignass Journal: United European Gastroenterol J Date: 2020-06-25 Impact factor: 4.623
Authors: Edward L Barnes; Millie D Long; Michael D Kappelman; Christopher F Martin; Robert S Sandler Journal: Inflamm Bowel Dis Date: 2019-06-18 Impact factor: 5.325
Authors: Roy Spijkerman; Lillian Hesselink; Carlo Bertinetto; Coen C W G Bongers; Falco Hietbrink; Nienke Vrisekoop; Luke P H Leenen; Maria T E Hopman; Jeroen J Jansen; Leo Koenderman Journal: Cytometry B Clin Cytom Date: 2021-03-08 Impact factor: 3.248
Authors: Bharati Kochar; Molly Aldridge; Suzanne Follan Cook; Renee Bright; Meaghan Mallette; Heather Moniz; Samir A Shah; Neal S LeLeiko; Jason Shapiro; Bruce E Sands; Wenli Chen; Elizabeth Jaeger; Joseph Galanko; Millie D Long; Christopher F Martin; Robert S Sandler; Michael D Kappelman Journal: J Med Internet Res Date: 2016-06-03 Impact factor: 5.428